More than 50 Years of Innovative Diagnostics

The DRG group is a leading manufacturer of clinical diagnostic and research ELISAs with distributors in over 110 countries. DRG is also the manufacturer of the DRG:HYBRiD-XL®, a fully automated analyzer for Immunoassays and Clinical Chemistry. Founded in 1970, DRG International, Inc. provides a complete range of products and services to the diagnostic and research communities. DRG International’s global headquarters is conveniently situated in Springfield, New Jersey.

The German division, DRG Instruments GmbH, was established in 1973 and is located in Marburg. Since 1990, DRG Instruments develops and manufactures innovative immunoassays, both for routine and research applications. With the expansion of DRG in the early nineties, further subsidiaries were founded in Poland, Russia, Czech Republic.

DRG is an ISO 13485:2016 certified company and operates in accordance the FDA 21 CFR 820 Quality System Regulation.

BioCheck, Inc., the parent company of DRG, is in San Francisco, California, USA and was founded in April 1997. BioCheck acquired DRG International with all offices in August 2021. BioCheck designs, develops, and manufactures high-quality, in vitro diagnostic immunoassay devices, for the worldwide biomedical, pharmaceutical, and scientific research markets. BioCheck is an ISO 13485:2016 certified and U.S. FDA 21 CFR Part 820 compliant company that provides quality products and is committed to best-in-class customer care.
Together with the DRG subsidiaries, BioCheck’s goal is to provide timely results and information so treatment can be implemented earlier, and effectiveness can be analyzed sooner to better the long-term outcomes or better life.